LUCIA
GONZALEZ CORTIJO
PROFESOR
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (11)
2024
2023
-
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Cancer Treatment and Research Communications, Vol. 37
-
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664
2022
-
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Nature Communications, Vol. 13, Núm. 1
2021
-
Mesothelial‐to‐mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer
International Journal of Molecular Sciences, Vol. 22, Núm. 21
2020
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2018
2015
-
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137
2006
-
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 889-895
2004
-
Initially Metastatic Breast Carcinoma Has a Distinct Disease Pattern but an Equivalent Outcome Compared with Recurrent Metastatic Breast Carcinoma
Cancer, Vol. 100, Núm. 9, pp. 1833-1842